Fikret Akyürek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fikret Akyürek has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Tuncez Akyurek
Department of Dermatology, Faculty of Medicine, University of Selçuk, Konya, Türkiye
9 shared publications - Fatma Sengul-Bag
Department of Biochemistry, Faculty of Pharmacy, University of Adıyaman, Adıyaman, Türkiye
8 shared publications - Halil Güven
Department of Medical Biochemistry, Faculty of Medicine, University of Selçuk, Konya, Türkiye
4 shared publications - Bahadir Ozturk
Department of Biochemistry, Faculty of Medicine, Selcuk University, Konya 42130, Turkey
3 shared publications - Duygu İlKe Yildirim
Selçuk Üniversitesi Tıp Fakültesi, Aile Hekimliği Anabilim Dalı
3 shared publications - Hüsamettin Vatansev
Department of Medical Biochemistry, Faculty of Medicine, Selcuk University, Konya, Turkey
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 57
Is increased inflammation in schizophrenia associated with increased cardiovascular risk and the etiopathogenesis of this disorder?
- 29 September 2026
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 57
Open AccessIs increased inflammation in schizophrenia associated with increased cardiovascular risk and the etiopathogenesis of this disorder?
- 17 July 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (8) , 3503-3513
Evaluation of the Relationships of Fisetin and Atorvastatin with Adipokine, Hepatokine, Myokine Profiles and Metabolic Parameters in Rats Fed with High-Fat Diet
- 17 July 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (8) , 3503-3513
Evaluation of the Relationships of Fisetin and Atorvastatin with Adipokine, Hepatokine, Myokine Profiles and Metabolic Parameters in Rats Fed with High-Fat Diet
- 20 May 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1)
Altered kynurenine pathway metabolism in patients with acne vulgaris
- 20 May 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1)
Altered kynurenine pathway metabolism in patients with acne vulgaris
- Open Access
- 14 April 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (3) , 1377-1386
Elevated serum cardiotrophin-1 and interleukin-17 levels in psoriasis
Background Psoriasis is a systemic, immune-mediated chronic disease in which the interleukin-23 (IL-23)/T-helper 17 (Th17) axis and its key effector cytokine, IL-17, play a central role. Cardiotrophin-1 (CT-1), a multifunctional cytokine from the IL-6 family, is involved in cardiovascular and metabolic homeostasis. This study aimed to evaluate serum levels of CT-1 and IL-17 in psoriasis, investigating their relationship with clinical parameters and their potential role as biomarkers for systemic inflammation and increased cardiometabolic risk. Methods This study included 64 patients diagnosed with psoriasis vulgaris and 64 age- and sex-matched healthy controls. Serum CT-1 and IL-17 levels were measured using enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). Results Serum levels of both CT-1 and IL-17 were significantly higher in the psoriasis group compared to the control group (p < 0.001 for each). A strong positive correlation was found between the two cytokines (ρ = 0.890, p < 0.001). CT-1 showed stronger correlations with lipid parameters than IL-17. However, no significant correlation was observed for either cytokine with PASI or DLQI. Receiver operating characteristic (ROC) analysis demonstrated that CT-1 had stronger diagnostic accuracy (AUC: 0.915, 95% CI:0.869–0.961) for distinguishing psoriasis patients from healthy controls compared to IL-17 (AUC: 0.733, 95% CI:0.645–0.822). Conclusions This study shows that CT-1 and IL-17 levels are significantly elevated in psoriasis and suggests that this increase may be associated with systemic inflammation and dyslipidemia. The observed discriminative performance of CT-1 supports its potential relevance as a marker of systemic inflammatory and cardiometabolic involvement, although its clinical utility requires further clarification.
- 14 April 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (3) , 1377-1386
Open AccessElevated serum cardiotrophin-1 and interleukin-17 levels in psoriasis
Background Psoriasis is a systemic, immune-mediated chronic disease in which the interleukin-23 (IL-23)/T-helper 17 (Th17) axis and its key effector cytokine, IL-17, play a central role. Cardiotrophin-1 (CT-1), a multifunctional cytokine from the IL-6 family, is involved in cardiovascular and metabolic homeostasis. This study aimed to evaluate serum levels of CT-1 and IL-17 in psoriasis, investigating their relationship with clinical parameters and their potential role as biomarkers for systemic inflammation and increased cardiometabolic risk. Methods This study included 64 patients diagnosed with psoriasis vulgaris and 64 age- and sex-matched healthy controls. Serum CT-1 and IL-17 levels were measured using enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). Results Serum levels of both CT-1 and IL-17 were significantly higher in the psoriasis group compared to the control group (p < 0.001 for each). A strong positive correlation was found between the two cytokines (ρ = 0.890, p < 0.001). CT-1 showed stronger correlations with lipid parameters than IL-17. However, no significant correlation was observed for either cytokine with PASI or DLQI. Receiver operating characteristic (ROC) analysis demonstrated that CT-1 had stronger diagnostic accuracy (AUC: 0.915, 95% CI:0.869–0.961) for distinguishing psoriasis patients from healthy controls compared to IL-17 (AUC: 0.733, 95% CI:0.645–0.822). Conclusions This study shows that CT-1 and IL-17 levels are significantly elevated in psoriasis and suggests that this increase may be associated with systemic inflammation and dyslipidemia. The observed discriminative performance of CT-1 supports its potential relevance as a marker of systemic inflammatory and cardiometabolic involvement, although its clinical utility requires further clarification.
- 10 April 2026
- Published by S. Karger AG in Neuropsychobiology
- p. 1-16
The Association of Kynurenine Pathway Metabolites with Neurocognitive Function in Unaffected Offspring of Parents with Bipolar Disorder
Introduction: The study aimed to investigate whether alterations in tryptophan (TRP) metabolites reflect dysregulation of the kynurenine (KYN) pathway, which has been implicated in bipolar disorder (BD), and to examine their relationship with cognitive functioning by assessing TRP metabolite levels alongside executive performance in non-affected offspring of individuals diagnosed with BD. Methods: The study included 32 healthy offspring of parents with BD type I as the case group and 31 healthy offspring of parents without any psychiatric disorders as controls. Psychiatric screening was conducted using the Turkish adaptation of the Schedule for Affective Disorders and Schizophrenia for School Age Children – Present and Lifetime Version (K-SADS-PL-DSM-5). Executive functioning was examined using a neuropsychological battery that included the Stroop, Serial Digit Learning (SDLT), and Cancellation (CT) tests. Serum levels of TRP, KYN, kynurenic acid (KYNA), 3-hydroxy kynurenine (3-HK), and 3-hydroxyanthranilic acid, as well as metabolite ratios (KYN/TRP, KYNA/KYN, 3-HK/KYN, and KYNA/3-HK), were measured. Logistic regression analysis was applied as part of the statistical approach to evaluate whether these metabolites and ratios could distinguish the offspring of individuals with BD from healthy controls. Results: Neurocognitive performance was significantly poorer in the case group than in the control group. Serum levels of TRP (t = 3.568, p = 0.001), KYN (t = 3.772, p = 0.001), KYNA (t = 2.797, p = 0.007), and the ratios of KYN/TRP (t = 2.550, p = 0.014) and KYNA/3-HK (z = −2.557, p = 0.011) were significantly decreased in cases, whereas KYNA/KYN (t = −2.562, p = 0.013) and 3-HK/KYN (z = −3.368, p = 0.001) ratios were significantly elevated. Correlation analyses showed significant associations between executive function deficits and TRP (r = 0.367, p = 0.039), KYN (r = 0.380, p = 0.032), KYNA (r = 0.488, p = 0.005), 3-HK (r = 0.492, p = 0.004), and the 3-HK/KYN ratio (r = 0.408, p = 0.020). Logistic regression analysis indicated that lower KYN levels distinguished cases from controls (OR = 0.986, 95% CI = 0.978–0.995, p = 0.002). Conclusions: The findings indicate that metabolism within the KYN pathway in the offspring of individuals with BD shows a shift toward its neurotoxic branch, reflected by increased 3-HK/KYN ratios and decreased KYNA-related indices, and this was associated with deficits in executive functioning. These findings indicate that alterations in TRP metabolism may play a role in altered cognitive processing among individuals with a familial predisposition to BD. Further research employing larger cohorts and dimensional analyses is needed to elucidate these relationships more precisely.
- 10 April 2026
- Published by S. Karger AG in Neuropsychobiology
- p. 1-16
The Association of Kynurenine Pathway Metabolites with Neurocognitive Function in Unaffected Offspring of Parents with Bipolar Disorder
Introduction: The study aimed to investigate whether alterations in tryptophan (TRP) metabolites reflect dysregulation of the kynurenine (KYN) pathway, which has been implicated in bipolar disorder (BD), and to examine their relationship with cognitive functioning by assessing TRP metabolite levels alongside executive performance in non-affected offspring of individuals diagnosed with BD. Methods: The study included 32 healthy offspring of parents with BD type I as the case group and 31 healthy offspring of parents without any psychiatric disorders as controls. Psychiatric screening was conducted using the Turkish adaptation of the Schedule for Affective Disorders and Schizophrenia for School Age Children – Present and Lifetime Version (K-SADS-PL-DSM-5). Executive functioning was examined using a neuropsychological battery that included the Stroop, Serial Digit Learning (SDLT), and Cancellation (CT) tests. Serum levels of TRP, KYN, kynurenic acid (KYNA), 3-hydroxy kynurenine (3-HK), and 3-hydroxyanthranilic acid, as well as metabolite ratios (KYN/TRP, KYNA/KYN, 3-HK/KYN, and KYNA/3-HK), were measured. Logistic regression analysis was applied as part of the statistical approach to evaluate whether these metabolites and ratios could distinguish the offspring of individuals with BD from healthy controls. Results: Neurocognitive performance was significantly poorer in the case group than in the control group. Serum levels of TRP (t = 3.568, p = 0.001), KYN (t = 3.772, p = 0.001), KYNA (t = 2.797, p = 0.007), and the ratios of KYN/TRP (t = 2.550, p = 0.014) and KYNA/3-HK (z = −2.557, p = 0.011) were significantly decreased in cases, whereas KYNA/KYN (t = −2.562, p = 0.013) and 3-HK/KYN (z = −3.368, p = 0.001) ratios were significantly elevated. Correlation analyses showed significant associations between executive function deficits and TRP (r = 0.367, p = 0.039), KYN (r = 0.380, p = 0.032), KYNA (r = 0.488, p = 0.005), 3-HK (r = 0.492, p = 0.004), and the 3-HK/KYN ratio (r = 0.408, p = 0.020). Logistic regression analysis indicated that lower KYN levels distinguished cases from controls (OR = 0.986, 95% CI = 0.978–0.995, p = 0.002). Conclusions: The findings indicate that metabolism within the KYN pathway in the offspring of individuals with BD shows a shift toward its neurotoxic branch, reflected by increased 3-HK/KYN ratios and decreased KYNA-related indices, and this was associated with deficits in executive functioning. These findings indicate that alterations in TRP metabolism may play a role in altered cognitive processing among individuals with a familial predisposition to BD. Further research employing larger cohorts and dimensional analyses is needed to elucidate these relationships more precisely.
- Open Access
- 24 February 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (2) , 737-744
Serum cardiotrophin-1 and interleukin-17 levels are elevated and correlate with disease severity in acne vulgaris
Background: Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit influenced by innate and adaptive immune responses. Interleukin-17 (IL-17) and cardiotrophin-1, two mediators involved in inflammation and metabolic stress, have been proposed as potential contributors to acne pathophysiology. This study aimed to compare serum IL-17 and cardiotrophin-1 levels between acne patients and healthy controls and to assess their relationship with disease severity. Methods: In this study, 57 acne patients and 57 healthy controls were enrolled. Serum IL-17 and cardiotrophin-1 levels were measured by ELISA. Acne severity was classified using the Global Acne Grading System. Lipid profiles and hematological parameters were also assessed. Results: Serum IL-17 and cardiotrophin-1 levels were significantly higher in the acne group compared to controls ( p < 0.001). Within the patient cohort, the severe acne subgroup had significantly higher levels of both cytokines than the mild acne subgroup. A positive correlation was found between IL-17 and cardiotrophin-1 (r = 0.549, p < 0.001), and both were correlated with acne severity (cardiotrophin-1: r = 0.735; IL-17: r = 0.453; p < 0.001). ROC analysis demonstrated high diagnostic accuracy for both biomarkers, with an AUC of 0.945 (95%CI:0.909–0.981) for cardiotrophin-1 and 0.904 (95%CI:0.852–0.956) for IL-17. Additionally, leukocyte, neutrophil, and platelet indices, as well as total cholesterol and high-density lipoprotein cholesterol levels, were significantly elevated in patients. Conclusions: The elevated levels of IL-17 and cardiotrophin-1 and their correlation with disease severity suggest their potential role as inflammatory biomarkers in acne. ROC analysis showed strong discrimination, but acne is clinically diagnosed; biomarkers require multicenter, longitudinal validation.
- 24 February 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (2) , 737-744
Open AccessSerum cardiotrophin-1 and interleukin-17 levels are elevated and correlate with disease severity in acne vulgaris
Background: Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit influenced by innate and adaptive immune responses. Interleukin-17 (IL-17) and cardiotrophin-1, two mediators involved in inflammation and metabolic stress, have been proposed as potential contributors to acne pathophysiology. This study aimed to compare serum IL-17 and cardiotrophin-1 levels between acne patients and healthy controls and to assess their relationship with disease severity. Methods: In this study, 57 acne patients and 57 healthy controls were enrolled. Serum IL-17 and cardiotrophin-1 levels were measured by ELISA. Acne severity was classified using the Global Acne Grading System. Lipid profiles and hematological parameters were also assessed. Results: Serum IL-17 and cardiotrophin-1 levels were significantly higher in the acne group compared to controls ( p < 0.001). Within the patient cohort, the severe acne subgroup had significantly higher levels of both cytokines than the mild acne subgroup. A positive correlation was found between IL-17 and cardiotrophin-1 (r = 0.549, p < 0.001), and both were correlated with acne severity (cardiotrophin-1: r = 0.735; IL-17: r = 0.453; p < 0.001). ROC analysis demonstrated high diagnostic accuracy for both biomarkers, with an AUC of 0.945 (95%CI:0.909–0.981) for cardiotrophin-1 and 0.904 (95%CI:0.852–0.956) for IL-17. Additionally, leukocyte, neutrophil, and platelet indices, as well as total cholesterol and high-density lipoprotein cholesterol levels, were significantly elevated in patients. Conclusions: The elevated levels of IL-17 and cardiotrophin-1 and their correlation with disease severity suggest their potential role as inflammatory biomarkers in acne. ROC analysis showed strong discrimination, but acne is clinically diagnosed; biomarkers require multicenter, longitudinal validation.
- Retracted
- 19 January 2026
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- p. 1-14
Evaluation of Cervicovaginal Melatonin Levels in Relation to HPV Infections and the Development of High-Grade Squamous Intraepithelial Lesions
Objectives: Human papillomavirus (HPV) infection establishes persistent infection in cervical epithelial cells, leading to Deoxyribonucleic Acid (DNA) damage, inflammation, and oxidative stress. This process predisposes to the development of precancerous lesions. Melatonin is believed to play a role in this pathogenesis, as it can inhibit viral persistence by reducing oxidative damage and modulating the immune response. This study aimed to investigate the effect of melatonin levels in cervicovaginal fluid on HPV infection leading to High-grade Squamous Intraepithelial Lesion (HSIL). Design: A total of 89 women aged 22–55 years were enrolled and divided into three groups: HPV-positive with HSIL (n=30), HPV-positive without HSIL (n=30), and HPV-negative controls (n=29)—prospective experimental melatonin marker study. Participants/Materials: Three groups were formed. The two HPV-positive groups were divided into those that developed HSIL and those that did not. The control group was then considered HPV and HSIL negative. Setting: The study was conducted at the Department of Obstetrics and Gynecology, Selçuk University Faculty of Medicine,2025. Methods: Melatonin levels were measured in all three groups. A total of 89 people were evaluated in the study, with 30 patients in each of the two HPV-positive groups and 29 patients in the control group. Results: No sociodemographic difference was found between the groups (p>.05). Melatonin levels were lower in the group developing HSIL than in the group not developing HSIL and the control group (p<.05). Limitations: However, this study is limited by a single-time measurement, a relatively small sample size, and a single-center design, which may restrict the generalizability of the findings. Conclusion: Low cervico-vaginal melatonin levels were significantly associated with HSIL progression, suggesting its potential role as a biomarker.
- 19 January 2026
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- p. 1-14
RetractedEvaluation of Cervicovaginal Melatonin Levels in Relation to HPV Infections and the Development of High-Grade Squamous Intraepithelial Lesions
Objectives: Human papillomavirus (HPV) infection establishes persistent infection in cervical epithelial cells, leading to Deoxyribonucleic Acid (DNA) damage, inflammation, and oxidative stress. This process predisposes to the development of precancerous lesions. Melatonin is believed to play a role in this pathogenesis, as it can inhibit viral persistence by reducing oxidative damage and modulating the immune response. This study aimed to investigate the effect of melatonin levels in cervicovaginal fluid on HPV infection leading to High-grade Squamous Intraepithelial Lesion (HSIL). Design: A total of 89 women aged 22–55 years were enrolled and divided into three groups: HPV-positive with HSIL (n=30), HPV-positive without HSIL (n=30), and HPV-negative controls (n=29)—prospective experimental melatonin marker study. Participants/Materials: Three groups were formed. The two HPV-positive groups were divided into those that developed HSIL and those that did not. The control group was then considered HPV and HSIL negative. Setting: The study was conducted at the Department of Obstetrics and Gynecology, Selçuk University Faculty of Medicine,2025. Methods: Melatonin levels were measured in all three groups. A total of 89 people were evaluated in the study, with 30 patients in each of the two HPV-positive groups and 29 patients in the control group. Results: No sociodemographic difference was found between the groups (p>.05). Melatonin levels were lower in the group developing HSIL than in the group not developing HSIL and the control group (p<.05). Limitations: However, this study is limited by a single-time measurement, a relatively small sample size, and a single-center design, which may restrict the generalizability of the findings. Conclusion: Low cervico-vaginal melatonin levels were significantly associated with HSIL progression, suggesting its potential role as a biomarker.
- Open Access
- 16 January 2026
- Published by Selcuk University in Genel Tıp Dergisi
- Vol. 36 (2026) , 1-5
Determination of Reference Interval of Serum Trimethylamine-N-Oxide In Humans By LC-MS/MS Method: Retrospective Study
Aim:The aim of our study is to determine the reference range of serum TMAO levels in individuals aged 18-65 using the LC-MS/MS method.Methods:TMAO levels in serum samples from 185 healthy individuals aged 18-65 were determined using the LC-MS/MS method. Statistical analysis classified the data by gender and age. The lower and upper limits with a 90% confidence interval were estimated using the robust method. Outliers were identified and excluded from the log-transformed data using the Tukey criterion. Skewness and kurtosis estimates were based on log-transformed data.Results:TMAO levels were similar between men and women, with median values of 180 ng/mL and 200 ng/mL, respectively (Z = –0.476, p=0.633). Additionally, no significant difference was observed in TMAO levels between women under 30 years of age and those aged 30 and above (median: 178 ng/mL vs. 186 ng/mL; Z = –0.739, p = 0.460). However, men aged 30 and above had significantly higher TMAO levels compared to men under 30 (median: 215 ng/mL vs. 191 ng/mL; Z = –2.225, p = 0.026). The reference interval for serum TMAO was determined as follows: 27–974 ng/mL in men under 30 years, 52–942 ng/mL in men aged 30 and above, 45–655 ng/mL in women under 30 years, and 33–539 ng/mL in women aged 30 and above.Conclusions:This study determined age- and gender-specific reference intervals for serum TMAO levels using the LC-MS/MS method. To our knowledge, this is the first study to establish such reference intervals using this analytical technique. The findings are expected to provide valuable data for future clinical and epidemiological studies involving TMAO as a biomarker.
- 16 January 2026
- Published by Selcuk University in Genel Tıp Dergisi
- Vol. 36 (2026) , 1-5
Open AccessDetermination of Reference Interval of Serum Trimethylamine-N-Oxide In Humans By LC-MS/MS Method: Retrospective Study
Aim:The aim of our study is to determine the reference range of serum TMAO levels in individuals aged 18-65 using the LC-MS/MS method.Methods:TMAO levels in serum samples from 185 healthy individuals aged 18-65 were determined using the LC-MS/MS method. Statistical analysis classified the data by gender and age. The lower and upper limits with a 90% confidence interval were estimated using the robust method. Outliers were identified and excluded from the log-transformed data using the Tukey criterion. Skewness and kurtosis estimates were based on log-transformed data.Results:TMAO levels were similar between men and women, with median values of 180 ng/mL and 200 ng/mL, respectively (Z = –0.476, p=0.633). Additionally, no significant difference was observed in TMAO levels between women under 30 years of age and those aged 30 and above (median: 178 ng/mL vs. 186 ng/mL; Z = –0.739, p = 0.460). However, men aged 30 and above had significantly higher TMAO levels compared to men under 30 (median: 215 ng/mL vs. 191 ng/mL; Z = –2.225, p = 0.026). The reference interval for serum TMAO was determined as follows: 27–974 ng/mL in men under 30 years, 52–942 ng/mL in men aged 30 and above, 45–655 ng/mL in women under 30 years, and 33–539 ng/mL in women aged 30 and above.Conclusions:This study determined age- and gender-specific reference intervals for serum TMAO levels using the LC-MS/MS method. To our knowledge, this is the first study to establish such reference intervals using this analytical technique. The findings are expected to provide valuable data for future clinical and epidemiological studies involving TMAO as a biomarker.
- 2 January 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (1) , 42-52
Investigation of the relationship between trimethylamine N-oxide, CD36, and CD38 levels in individuals with a high triglyceride/HDL-cholesterol ratio
The Triglyceride/HDL-Cholesterol (TG/HDL-C) ratio is a recognized biomarker for cardiovascular risk, linked to atherogenic dyslipidemia and insulin resistance. Recent evidence also implicates molecules like trimethylamine N-oxide (TMAO), CD36, and CD38 in metabolic inflammation and atherosclerosis. This study investigated the relationship between TMAO, CD36, and CD38 in individuals with a high TG/HDL-C ratio. A total of 82 volunteer individuals with no known cardiac disease were enrolled in the study (41 dyslipidemic individuals and 41 healthy controls). Serum TMAO levels from participants were quantitatively measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The surface expression levels of CD36 and CD38 on the monocyte population were assessed by flow cytometry. The plasma atherogenic index (PAI) was calculated using the log(TG/HDL-C) formula to assess the atherogenic risk status. The TG/HDL-C ratio, TMAO level, and CD38 expressions were significantly higher in the dyslipidemia group compared to the control group (p < 0.05). Additionally, low-density lipoprotein cholesterol levels and HOMA-IR scores were higher in dyslipidemic individuals. According to the PAI assessment, the entire dyslipidemia group was in the high cardiovascular risk category. The TG/HDL-C ratio showed a positive correlation with TMAO and CD38 levels. The positive relationship between the TG/HDL-C ratio and TMAO and CD38 levels suggests that these parameters could be evaluated together to reflect cardiovascular risk. However, given the cross-sectional design of the study, these findings indicate associations rather than causal relationships, and metabolic and inflammatory markers may reflect early stages of subclinical atherosclerosis in individuals without known cardiovascular disease.
- 2 January 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (1) , 42-52
Investigation of the relationship between trimethylamine N-oxide, CD36, and CD38 levels in individuals with a high triglyceride/HDL-cholesterol ratio
The Triglyceride/HDL-Cholesterol (TG/HDL-C) ratio is a recognized biomarker for cardiovascular risk, linked to atherogenic dyslipidemia and insulin resistance. Recent evidence also implicates molecules like trimethylamine N-oxide (TMAO), CD36, and CD38 in metabolic inflammation and atherosclerosis. This study investigated the relationship between TMAO, CD36, and CD38 in individuals with a high TG/HDL-C ratio. A total of 82 volunteer individuals with no known cardiac disease were enrolled in the study (41 dyslipidemic individuals and 41 healthy controls). Serum TMAO levels from participants were quantitatively measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The surface expression levels of CD36 and CD38 on the monocyte population were assessed by flow cytometry. The plasma atherogenic index (PAI) was calculated using the log(TG/HDL-C) formula to assess the atherogenic risk status. The TG/HDL-C ratio, TMAO level, and CD38 expressions were significantly higher in the dyslipidemia group compared to the control group (p < 0.05). Additionally, low-density lipoprotein cholesterol levels and HOMA-IR scores were higher in dyslipidemic individuals. According to the PAI assessment, the entire dyslipidemia group was in the high cardiovascular risk category. The TG/HDL-C ratio showed a positive correlation with TMAO and CD38 levels. The positive relationship between the TG/HDL-C ratio and TMAO and CD38 levels suggests that these parameters could be evaluated together to reflect cardiovascular risk. However, given the cross-sectional design of the study, these findings indicate associations rather than causal relationships, and metabolic and inflammatory markers may reflect early stages of subclinical atherosclerosis in individuals without known cardiovascular disease.
- Open Access
- 12 November 2025
- Published by Springer Nature in Research Square
Evaluation of the Relationships of Fisetin and Atorvastatin with Adipokine, Hepatokine, Myokine Profiles and Metabolic Parameters in Rats Fed with High-Fat Diet
Objective The aim of this study is to evaluate the effects of fisetin and atorvastatin administration on metabolic parameters and adipokine, hepatokine, and myokine profiles in rats fed a high-fat diet (HFD). Additionally, the effects of these agents on liver and skeletal muscle histology were investigated. Methods In the study, male Sprague-Dawley rats were randomly divided into five groups: K(Control), Y(HFD), YF(HFD + Fisetin), YA(HFD + Atorvastatin) and YAF(HFD + Atorvastatin + Fisetin). The Y groups were fed a high-fat diet for 8 weeks. The intervention groups were administered fisetin (50 mg/kg/day) and atorvastatin (10 mg/kg/day) orally via gavage in addition to the high-fat diet for 8 weeks. At the end of the study, blood biochemistry, asprosin, fetuin-A, GDF-15, Metrnl, and histological changes in liver and gastrocnemius muscle tissue were examined. Results Histopathological examinations revealed significant structural damage in liver and muscle tissues in groups treated with HFD, while these damages were significantly reduced in the combined treatment group. However, limited effects were observed on LDL-C and TG levels in the biochemical data; an increase in total cholesterol, a decrease in glucose levels, and improvements in creatinine and urea levels were detected. No significant differences were observed in adipokine, hepatokine, and myokine levels between the groups. Conclusion The combination of fisetin and atorvastatin significantly reduced HFD-induced liver and muscle tissue damage at the histological level. In terms of biochemical parameters, the combination therapy may be protective at the tissue level, but its effects on metabolic regulation may be limited depending on the dose and duration. Therefore, pharmacodynamic interactions and optimal dosage should be investigated in more detail.
- 12 November 2025
- Published by Springer Nature in Research Square
Open AccessEvaluation of the Relationships of Fisetin and Atorvastatin with Adipokine, Hepatokine, Myokine Profiles and Metabolic Parameters in Rats Fed with High-Fat Diet
Objective The aim of this study is to evaluate the effects of fisetin and atorvastatin administration on metabolic parameters and adipokine, hepatokine, and myokine profiles in rats fed a high-fat diet (HFD). Additionally, the effects of these agents on liver and skeletal muscle histology were investigated. Methods In the study, male Sprague-Dawley rats were randomly divided into five groups: K(Control), Y(HFD), YF(HFD + Fisetin), YA(HFD + Atorvastatin) and YAF(HFD + Atorvastatin + Fisetin). The Y groups were fed a high-fat diet for 8 weeks. The intervention groups were administered fisetin (50 mg/kg/day) and atorvastatin (10 mg/kg/day) orally via gavage in addition to the high-fat diet for 8 weeks. At the end of the study, blood biochemistry, asprosin, fetuin-A, GDF-15, Metrnl, and histological changes in liver and gastrocnemius muscle tissue were examined. Results Histopathological examinations revealed significant structural damage in liver and muscle tissues in groups treated with HFD, while these damages were significantly reduced in the combined treatment group. However, limited effects were observed on LDL-C and TG levels in the biochemical data; an increase in total cholesterol, a decrease in glucose levels, and improvements in creatinine and urea levels were detected. No significant differences were observed in adipokine, hepatokine, and myokine levels between the groups. Conclusion The combination of fisetin and atorvastatin significantly reduced HFD-induced liver and muscle tissue damage at the histological level. In terms of biochemical parameters, the combination therapy may be protective at the tissue level, but its effects on metabolic regulation may be limited depending on the dose and duration. Therefore, pharmacodynamic interactions and optimal dosage should be investigated in more detail.